Elvitegravir (GS 9137)

Once-Daily Elvitegravir Matches Raltegravir in Phase 3 Study
3-25-2011

Gilead Begins First Phase 3 Clinical Trial of Boosted Elvitegravir Quad Pill
4-16-2010

Gilead's Quad Pill Matches Atripla, New Booster Cobicistat (GS 9350) Looks Good with Atazanavir (Reyataz)
2-19-2010

Gilead Releases 24 Week Data on "Quad" Pill containing Elvitegravir and Experimental Boosting Agent GS 9350
1/08/10


Gilead Plans Clinical Trial of 4-in-1 Antiretroviral Combination Pill Containing Experimental Integrase Inhibitor Elvitegravir
- 1/20/09

Gilead Announces Start of Phase III Efficacy Trial of Experimental Integrase Inhibitor Elvitegravir in Treatment-experienced HIV Patients
7/25/08